Strategic Initiative

Slingshot members are tracking this corporate initiative:

Neurocrine Biosciences (NBIX) and Xenon Pharmaceuticals(XENE) Announce Agreement to Develop First-in-Class Treatments for Epilepsy

Source Link:: http://investor.xenon-pharma.com/news-releases/news-release-details/neurocrine-biosciences-and-xenon-pharmaceuticals-announce

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

XENE

100%

NBIX

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details Neurocrine Biosciences Gains Rights to XEN901, a Clinical Stage Selective Nav1.6 Sodium Channel Inhibitor, Being Developed for the Treatment of Epilepsy Xenon Receives $50 Million Upfront and Up to $1.7 Billion in Potential Development, Regulatory and Commercial Milestone Payments Across All Licensed Products, as well as Option to Co-Fund XEN901

http://investor.xeno...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Strategic Initiative Date

Announcement Date:

Dec 02, 2019

Projected Implementation:

Q4, 2019

Relevance Tracked Until:

Q1, 2020

Related Projects

Don’t see a project related to the strategic initiative you care about?

Related Keywords Epilepsy, Xen901, Nav1.6 Sodium Channel Inhibitor